At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REVBW Revelation Biosciences, Inc.
Trading 04-02 11:39:33 EDT
0.0100
+0.0000
0.00%
High0.0100Low0.0100Vol0.00
Open0.0100D1 Closing0.0100Amplitude0.00%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O115.23T/O Rate--Tradable Shares0.00
P/B0.00ROE-264.85%EPS0.00
52wk High0.041352wk Low0.0040P/E--
Dividend0.00Div.Yield0.00ROA-52.93%
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Business Wire  ·  03-17
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
Business Wire  ·  03-13
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
REVB Starts 2025 With Bright Future Ahead
Zacks Small Cap Research  ·  03-07
REVB Starts 2025 With Bright Future Ahead
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Business Wire  ·  03-06
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Business Wire  ·  02-26
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Business Wire  ·  02-24
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
REVB Start 1B Trial and Announces Split
Zacks Small Cap Research  ·  01-29
REVB Start 1B Trial and Announces Split
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
Business Wire  ·  01-24
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Business Wire  ·  01-21
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Business Wire  ·  01-13
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
Business Wire  ·  01-06
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Business Wire  ·  2024-12-03
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
REVB Gets FDA Go Ahead
Zacks Small Cap Research  ·  2024-12-02
REVB Gets FDA Go Ahead
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Business Wire  ·  2024-12-02
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Business Wire  ·  2024-11-12
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
REVB Results Set Stage for Future Growth
Zacks Small Cap Research  ·  2024-11-11
REVB Results Set Stage for Future Growth
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
Business Wire  ·  2024-09-24
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10

Introduction

Company Name.
Revelation Biosciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App